

**NeoTract Announces the Designation of
Michigan Institute of Urology as UroLift® Center of Excellence**

*Designation Recognizes Dr. James Relle's Commitment to Exemplary Care,
Deep UroLift® Experience*

TROY, MI – Michigan Institute of Urology (MIU) is proud to be designated as a UroLift® Center of Excellence, with Dr. James Relle recognized as its physician champion. The designation recognizes that Dr. Relle has achieved a high level of training and experience with the UroLift System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia or BPH.

“The UroLift System is a breakthrough minimally invasive treatment that typically takes less than an hour and can offer multiple benefits for men with enlarged prostate – no cutting, heating, or removal of tissue, minimal downtime, no compromise of sexual function, and no need for continued medications,” said Dr. Relle. “In addition, the UroLift System doesn’t interfere with sexual function. I am proud to be a national leader in treating patients with this durable and effective treatment.”

Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Five-year data from a randomized study shows the UroLift System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief.¹ A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.²

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.

Several MIU physicians are experienced in the use and administration of UroLift® and are able to offer this breakthrough technique to our patients suffering from symptoms related to BPH.

About the UroLift System

NeoTract’s FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks

after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.

About Michigan Institute of Urology (MIU)

As one of the longest standing and largest sub-specialty Urology practices in the State of Michigan, MIU is dedicated to provide patients the most up to date, state of the art urologic care. Their specialists have been recruited from the most sophisticated university centers in the United States and are available at all of their 22 office locations. MIU's administrative staff follows strict guidelines to insure cost effective quality medical care is provided. Michigan Institute of Urology, P.C., is comprised of 44 General and Fellowship Trained Urologists, a Pathologist and Radiologist. The MIU team also includes a complement of compassionate, caring Nurse Practitioners, Registered Nurses, Medical Assistants and Ancillary Personnel. Learn more at www.michiganurology.com/

#

Media Contact:

Amy Cramer
Amy(at)healthandcommerce(dot)com
M: 650-391-3714

¹ Roehrborn et al. EAU Abstract_ Eur Urol Suppl 2017; 16(3):e192.

² Sonksen et al J Urology 2016

MAC00359-01 Rev C